The IP introduces a novel methodology aimed at tackling autosomal dominant genetic disorders. By harnessing the power of CRISPR technology and guided RNA (gRNA) design, this IP offers a targeted approach to address mutant alleles while preserving the expression of healthy alleles. It can precisely target mutant alleles associated with autosomal dominant disorders, paving the way for potential therapeutic interventions. Unlike conventional approaches, this methodology leverages specific gRNA design, incorporating mutated sequences adjacent to the protospacer adjacent motif (PAM) sequence. This allows for the selective targeting of mutant alleles and minimizes off-target effects and preserving the expression of healthy alleles. At its current stage, proof-of-concept experiments have demonstrated the efficacy of gRNAs targeting mutant alleles associated with specific disorders. Future development efforts will focus on expanding the scope of application to other autosomal dominant genetic disorders and refining the methodology for clinical translation. Its tailored approach to gRNA design offers enhanced precision and specificity, reducing the risk of unintended genetic modifications. The IP has broad utility and commercial potential; the versatility of CRISPR technology allows for its potential application in a wide range of autosomal dominant disorders beyond the initial target.